ROS1 and pancreatic neoplasm: Recently, an incidence of VTE greater than 30% has been described in patients with pancreatic cancer and in specific molecular subtypes of non-small cell lung cancer with ROS-1 and ALK rearrangement.69, 70, 71, 72